Grant: Master's Award: Canada Graduate Scholarships
University of Saskatchewan
$27,000.00
Investigating Alterations in Gene Expression in the Gut with GIP Receptor and GLP-1 Receptor Dual Agonism
EF 2024-25
Résumé
Improper fat processing in the gut causes lipid disorder that leads to heart disease and strokes. Tirzepatide is a novel drug that activates two peptide hormone receptors at the same time. In clinical trials, it lowers blood sugar and causes weight loss, thus showing strong efficacy for treating type 2 diabetes and obesity. Additionally, it improves blood lipids, the mechanism of which is unknown. Tirzepatide treatment makes patients handle dietary fats better, suggesting a role in changing how the gut processes fats. This study aims to elucidate the molecular mechanisms of Tirzepatide on gut lipid processing. Rats will be fed either a high-fat diet or a control diet for 8 weeks and treated with Tirzepatide or placebo during their final week of feeding. Gut tissues will be collected at the end of treatments. Spatial gene expression will be performed on gut tissues using a cutting-edge technique that combines histology and spatially resolved whole transcriptome gene expression profiling to localize and quantify gene expression in the context of tissue architecture, tissue microenvironments, and cell groups. Comparisons of gene expression will be made between drugs (tirzepatide vs placebo) within each dietary treatment, and between diets (high-fat vs control diet) within each drug treatment. This will identify key genes in specific locations and cell types in the gut affected by simultaneous activation of two hormone receptors. Findings from this study will elucidate how gut lipid handling is regulated and help develop novel drugs to prevent and treat lipid disorders, heart disease and strokes.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529982
Name
Minier Ethan E
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating Alterations in Gene Expression in the Gut with GIP Receptor and GLP-1 Receptor Dual Agonism
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diabetes; Gene Expression; Gut; Lipids; Obesity; Tirzepatide
Abstract
Improper fat processing in the gut causes lipid disorder that leads to heart disease and strokes. Tirzepatide is a novel drug that activates two peptide hormone receptors at the same time. In clinical trials, it lowers blood sugar and causes weight loss, thus showing strong efficacy for treating type 2 diabetes and obesity. Additionally, it improves blood lipids, the mechanism of which is unknown. Tirzepatide treatment makes patients handle dietary fats better, suggesting a role in changing how the gut processes fats. This study aims to elucidate the molecular mechanisms of Tirzepatide on gut lipid processing. Rats will be fed either a high-fat diet or a control diet for 8 weeks and treated with Tirzepatide or placebo during their final week of feeding. Gut tissues will be collected at the end of treatments. Spatial gene expression will be performed on gut tissues using a cutting-edge technique that combines histology and spatially resolved whole transcriptome gene expression profiling to localize and quantify gene expression in the context of tissue architecture, tissue microenvironments, and cell groups. Comparisons of gene expression will be made between drugs (tirzepatide vs placebo) within each dietary treatment, and between diets (high-fat vs control diet) within each drug treatment. This will identify key genes in specific locations and cell types in the gut affected by simultaneous activation of two hormone receptors. Findings from this study will elucidate how gut lipid handling is regulated and help develop novel drugs to prevent and treat lipid disorders, heart disease and strokes.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Minier, Ethan E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~